A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Cilag S.A.S.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant with a confirmed diagnosis of Psoriatic Arthritis (PsA) according to the dermatological and/or rheumatologic routine practice, using different diagnosis tools, example, the Classification criteria for Psoriatic Arthritis (CASPAR), or others
Participant must be starting ustekinumab for PsA according to the local labelling, as a first (biological naïve participant), or second line (biological experienced participants) of bDMARD therapy: First line bDMARD therapy: The first line therapy includes all bio-naïve participants who start their ustekinumab as their first biologic treatment at the study start (within a maximum 1-month window after the baseline visit); Second line bDMARD therapy: The second line therapy includes participants who initiated ustekinumab as their second biologic therapy at the study start (within a maximum 1-month window after the baseline visit)
Participant for which the ustekinumab treatment has been decided by the investigator prior to and independently of the participant's inclusion into the study
Participant for which the first administration of the ustekinumab treatment will occur within the 4-week period from inclusion assessment
Participant has signed an informed consent form
You may not be if
Participant starting ustekinumab as a third or further line of bDMARD therapy
Already ustekinumab-experienced participants
Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within at least 30 days before the start of the study or more according to the half-life of the investigational drug
Participant has refused to participate in the study or unable to give his consent
Clareo Health | A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
